Lymphocyte Immunization Therapy (LIT) is an immunological treatment that has been proposed for certain cases of recurrent pregnancy loss. It involves administering lymphocytes, a type of white blood cell, obtained from another person—often the male partner—with the aim of modifying the recipient's immune response.
LIT has been explored because researchers have investigated whether immune-related factors contribute to some pregnancy losses. However, current evidence has not established LIT as a safe and effective routine treatment for unexplained recurrent pregnancy loss. The American Society for Reproductive Medicine and the European Society of Human Reproduction and Embryology do not recommend its routine use for this purpose. <Cite refs={["turn248630search0","turn248630search1"]}/>
At Birla Fertility & IVF, Noida, Dr. Megha Jindal, Center Head, can help patients understand recurrent pregnancy loss, available investigations and treatment options based on their individual medical history.
Lymphocytes are white blood cells involved in the body's immune response. LIT has been proposed on the theory that exposure to another person's lymphocytes may alter certain immune responses associated with pregnancy.
The treatment has historically been investigated in people experiencing recurrent pregnancy loss, particularly when no clear cause has been identified. However, the biological explanation for its proposed benefit remains uncertain, and research has not consistently demonstrated improved live-birth outcomes.
LIT should not be presented as a proven treatment for miscarriage or as a guaranteed way to improve pregnancy outcomes.
Recurrent pregnancy loss refers to repeated pregnancy losses. Possible contributing factors include chromosomal abnormalities, uterine conditions, certain hormonal or medical disorders, and specific immune-related conditions.
Some researchers have investigated whether immune mechanisms may contribute to a subset of pregnancy losses. LIT developed from one such proposed explanation, but the clinical evidence supporting its use remains insufficient.
A thorough evaluation is important because recurrent pregnancy loss can have multiple causes, and the appropriate management depends on the findings. Immune treatments should not be assumed to be necessary simply because a person has experienced repeated miscarriages.
The proposed process involves exposing the recipient to lymphocytes from another person in an attempt to influence immune responses.
The theory suggests that this exposure might change how the maternal immune system responds during pregnancy. However, the relationship between the proposed immune mechanisms and successful pregnancy outcomes has not been established sufficiently to support routine treatment.
The proposed mechanism should therefore be understood as a hypothesis rather than a proven explanation for recurrent miscarriage.
Evidence from clinical studies and systematic reviews has been inconsistent. Some analyses have reported possible benefits in selected study populations, while other assessments have found no significant improvement in live-birth outcomes.
Professional guidance remains cautious. The ASRM's 2026 committee opinion states that routine immune testing and treatment are not recommended for recurrent pregnancy loss and notes that studies have not demonstrated benefit from routine LIT for unexplained recurrent pregnancy loss. ESHRE guidance has also advised against LIT for unexplained recurrent pregnancy loss because of the lack of established benefit and potential serious adverse effects. <Cite refs={["turn248630search0","turn248630search1","turn248630search5"]}/>
For this reason, LIT should not be marketed as an established fertility treatment. Patients considering it should receive clear information about the uncertainty of its benefits, possible risks and evidence-based alternatives.
Because LIT involves administering cells from another person, it raises safety concerns that should be discussed with a qualified clinician.
Potential concerns include:
Infectious risk: There may be a risk of transmitting infections through donor-derived cells if appropriate screening and safeguards are inadequate.
Immune complications: Exposure to another person's cells may lead to immune reactions, including the development of antibodies that could have implications for pregnancy.
Uncertain benefit: Patients may undergo treatment without a demonstrated improvement in the chance of a live birth.
Treatment-related costs and delays: Additional procedures may add expense and delay investigations or treatments with stronger supporting evidence.
The extent of risk depends on the circumstances and procedures used. Patients should not assume that LIT is risk-free simply because it is described as immunotherapy.
For people experiencing repeated miscarriages, a structured evaluation can help identify possible causes and guide appropriate care.
Depending on the individual's history, assessment may include:
Reviewing previous pregnancy losses and relevant medical records.
Evaluating the uterus for structural abnormalities when indicated.
Assessing for specific medical or hormonal conditions.
Considering genetic evaluation or counselling where appropriate.
Investigating antiphospholipid syndrome when clinically indicated.
Reviewing previous fertility treatment and discussing relevant next steps.
Not every patient needs every test. The investigation plan should be individualised, and treatment should target identified conditions where effective options are available.
At Birla Fertility & IVF, Noida, Dr. Megha Jindal, Center Head, can help patients review their reproductive history, previous investigations and fertility treatment options.
If you have experienced recurrent miscarriage or unsuccessful fertility treatment, a consultation can help clarify which investigations may be appropriate and which treatments have evidence supporting their use.
Any discussion of LIT should include its uncertain effectiveness, possible risks and the recommendations of relevant professional guidelines. The aim should be to support informed decisions without making promises about pregnancy outcomes.
LIT stands for Lymphocyte Immunization Therapy. It is an immunological treatment that has been investigated for recurrent pregnancy loss and involves administering lymphocytes obtained from another person.
No. Current evidence does not establish LIT as a safe and effective routine treatment for unexplained recurrent pregnancy loss. Major professional guidelines advise against its routine use for this purpose. <Cite refs={["turn248630search0","turn248630search1"]}/>
LIT is based on the theory that exposure to another person's lymphocytes may modify certain immune responses relevant to pregnancy. This proposed mechanism has not been sufficiently validated to establish the treatment's clinical benefit.
LIT is not routinely recommended for unexplained recurrent pregnancy loss. A specialist evaluation can help identify possible causes of miscarriage and determine whether other evidence-based investigations or treatments are appropriate.
No. LIT cannot guarantee conception, prevent miscarriage or ensure a live birth. Its effectiveness remains uncertain, and its potential risks should be carefully considered.
Yes. Because the treatment involves cells from another person, potential concerns include infectious transmission and immune complications. The safety evidence is limited, and patients should discuss these risks with a qualified clinician before considering any such procedure.
No. Routine immune testing and treatment are not recommended for every patient with recurrent pregnancy loss. Testing should be guided by clinical history and evidence-based recommendations. <Cite refs={["turn248630search0","turn248630search8"]}/>
Alternatives depend on the cause of pregnancy loss. A specialist may recommend targeted evaluation and treatment for identified conditions, genetic counselling when appropriate, or supportive follow-up when no cause is found. There is no single treatment suitable for everyone.
Unsuccessful IVF cycles do not automatically indicate an immune problem. A fertility specialist should review the treatment history, embryo information, uterine assessment and other relevant factors before considering additional investigations or treatments.
You can arrange a fertility consultation at Birla Fertility & IVF, Noida, with Dr. Megha Jindal, Center Head, to discuss your history, relevant investigations and treatment options.
If you have experienced repeated miscarriages or have concerns about immune-related fertility treatments, consult the fertility team at Birla Fertility & IVF, Noida. Dr. Megha Jindal, Center Head, can help you understand the available evaluation and treatment options in the context of your medical history.
Write a Reply or Comment